New study demonstrates long-term pain relief for patients implanted with Abbott’s proprietary BurstDR spinal cord stimulation (SCS) at four-year follow up.

The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease.

The partnership with Medtronic will enable continuous glucose monitoring (CGM) sensors based on Abbott's FreeStyle Libre sensing technology to integrate with Medtronic's insulin delivery systems.

TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide.

Liberta RC™ deep brain stimulation (DBS) system features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system.

With this new approval, people with a Proclaim™ DRG neurostimulation system can soon receive full-body MRI scans.

Tandem’s Control-IQ™ hybrid closed-loop technology now integrates with the first and only 15-day continuous glucose monitoring (CGM) sensor in the U.S.

GLP systems Track™ reduces turnaround time and removes at least 80% of manual steps, increasing reliability and minimizing errors to help provide patients quicker lab results.

Abbott's new HPV test uses molecular technology to provide genotype determination on the 14 high-risk, cancer-causing types of HPV.

Abbott's new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time after it's opened a clogged artery.